Why the study?
Does the DESyne novolimus-eluting coronary stent reduce device- and patient-oriented events compared to the Endeavor zotarolimus-eluting coronary stent?
Does the DESyne novolimus-eluting coronary stent reduce device- and patient-oriented events compared to the Endeavor zotarolimus-eluting coronary stent?
The DESyne novolimus-eluting stent demonstrated significantly lower device- and patient-oriented events compared to the Endeavor zotarolimus-eluting stent at 5 years, though larger studies are needed to confirm clinical outcomes.
Supports DESyne novolimus-eluting stent use in PCI; extends long-term RCT evidence versus zotarolimus-eluting platforms.
At five-year follow-up, the incidence of device- and patient-oriented events was significantly lower in the NES group. Further studies, adequately powered for clinical outcomes, are warranted.
No takes yet. Share an insight, caveat, or question.
Iqbal et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: